Table 3. Feature analysis of the indications approved in the European Union and the independent claims of the patent families 2 – 10.

Disease		Stratification		Patient history		Combination with		Therapy modalities		Dosage
1	low grade/ follicular NHL	1	stage III - IV	1	chemoresistant or in second or higher relapse after chemotherapy/relapsed following chemotherapy or refractory to chemotherapy	1	CVP	1	patient received at least one prior course of treatment with rituximab 24 - 40 wk ago	1	375 mg/m2 every week for 4 wk
2	diffuse large B-Cell NHL/bulky disease	2	older 60 y	2	previously untreated	2	CHOP	2	maintenance therapy	2	375 mg/m2 on day 1 of each chemotherapy cycle, for up to 8 cycles
3	RA/Joint damage	3	40 x 1029 to about 200 x 1029 white blood cells per liter	3	relapsed or refractory, but responding to induction chemotherapy	3	Chemotherapy	3	administered within 5 min	3	375 mg/m2 every 3 mo, starting 3 mo after induction, for max 2 y
4	CLL			4	adult patients with inadequate response or intolerance to other antirheumatic drugs including TNF inhibitors/Inadequate response to TNF inhibitor	4	MTX			4	375 mg/m2 every 2 mo, starting 2 mo after induction, for max 2 y
5	GPA and MPA			5	first line treatment	5	Glucocorticoids			5	2 dosages of 1000 mg iv, separated by 2 wk
1 or 2	NHL			6	previously untreated and relapsed/ refractory	6	recombinant hyaluronidase			6	375 mg/m2 on day 0, followed by 6 cycles of 500 mg/m2
1 or 2 or 3	hematologic malignancy			7	induction of remission in adult patients					7	500 - 1500 mg/m2
										8	750 mg - 1100 mg, 2 times/month
										9	1400mg solution for sc injection